Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

canopy-health.ca

Stage

Acquired | Acquired

About Canopy Health Innovations

Canopy Health Innovations is a biopharmaceutical company focused on developing innovative cannabis-based related products.

Canopy Health Innovations Headquarters Location

55 St. Clair Avenue West Suite 202

Toronto, Ontario, M4V 2Y7,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Canopy Health Innovations

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Canopy Health Innovations is included in 1 Expert Collection, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Canopy Health Innovations Patents

Canopy Health Innovations has filed 2 patents.

The 3 most popular patent topics include:

  • Cannabinoids
  • Designer drugs
  • Analgesics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/1/2019

9/7/2021

Cannabinoids, Designer drugs, Phenols, Analgesics, Piperidines

Grant

Application Date

11/1/2019

Grant Date

9/7/2021

Title

Related Topics

Cannabinoids, Designer drugs, Phenols, Analgesics, Piperidines

Status

Grant

Latest Canopy Health Innovations News

Over-the-counter CBD products often mislabeled, with many containing THC

Jul 20, 2022

Disclosures: Spindle reports serving as a consultant for Canopy Health Innovations Inc. Vandrey reports receiving personal fees from Canopy Health Innovations, MyMD Pharmaceuticals, Mira1a Therapeutics Inc., Syqe Medical Ltd., Radicle Science Inc. and WebMD. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Researchers found that topical CBD products purchased online and in retail stores were often inaccurately labeled, and many contained THC, highlighting the need for improved regulatory oversight, according to a report in JAMA Network Open. Tory R. Spindle, PhD, assistant professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine, and colleagues assessed label accuracy of topical CBD products and quantified their therapeutic and nontherapeutic claims. Source: Adobe Stock. “Misleading labels can result in people using poorly regulated and expensive CBD products instead of FDA-approved products that are established as safe and effective for a given health condition,” Spindle said in a related press release. Researchers purchased 105 hemp products — 45 from retail stores in Baltimore and 60 online — that were intended for topical or transdermal application and claimed to contain CBD. Of 89 products that listed the total amount of CBD on the label, 18% were over-labeled (contained > 10% less CBD than advertised), 58% were under-labeled (contained > 10% more than advertised), and 24% were accurately labeled. The authors reported that the median percentage deviation between the actual amount of CBD and the labeled amount was 21% (range, –75% to 93%) for in-store products and 10% (–96% to 121%) for online products. This indicated that, overall, products contained more CBD than advertised. They also reported that THC was detected in 37 of the 105 products (35%) included in the study. However, all contained less than 0.3%. Of the 37 products that contained THC, four were labeled THC-free, 14 were advertised as containing less than 0.3%, and 19 did not reference THC on the label. Overall, 28% of products made therapeutic claims, 14% made cosmetic claims, and 47% indicated they were not FDA-approved. “The variability in the chemical content and labeling found in our study highlights the need for better regulatory oversight of CBD products to ensure consumer safety,” Ryan Vandrey, PhD, study co-author and professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine, said in the release. Reference: Study shows widespread mislabeling of CBD content occurs for over-the-counter products. https://www.hopkinsmedicine.org/news/newsroom/news-releases/study-shows-widespread-mislabeling-of-cbd-content-occurs-for-over-the-counter-products . Published July 20, 2022. Accessed July 20, 2022. Read more about

  • Where is Canopy Health Innovations's headquarters?

    Canopy Health Innovations's headquarters is located at 55 St. Clair Avenue West, Toronto.

  • What is Canopy Health Innovations's latest funding round?

    Canopy Health Innovations's latest funding round is Acquired.

  • Who are the investors of Canopy Health Innovations?

    Investors of Canopy Health Innovations include Spectrum Cannabis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.